
ACHV Stock Forecast & Price Target
ACHV Analyst Ratings
Bulls say
Achieve Life Sciences Inc. shows a promising outlook due to the validated mechanism and robust clinical efficacy of its key product, cytisinicline, which addresses a significant market need for smoking and vaping cessation therapies. The company's recent sales figures indicate a potential market size of $1.6 billion, with further growth anticipated from the expansion of vaping-related labeling. Additionally, the favorable safety profile and flexible dosing options of cytisinicline are expected to enhance patient adherence and broaden its adoption, contributing to long-term growth and share appreciation.
Bears say
Achieve Life Sciences Inc. faces a negative outlook primarily due to concerns regarding the commercial viability of cytisinicline despite its demonstrated efficacy in clinical trials, as slow adoption rates are anticipated in the cigarette smoking indication. The company's projections have been adjusted downward, with peak market penetration in the vaping segment reduced from 10% to 8%, reflecting skepticism about market acceptance and adoption. Additionally, the need for competitive differentiation is heightened by observations that other treatments like bupropion may be encountering similar outcomes regarding patient interest in smoking cessation, further complicating Achieve's market positioning.
This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
ACHV Analyst Forecast & Price Prediction
Start investing in ACHV
Order type
Buy in
Order amount
Est. shares
0 shares